baseimmune.

®

TM

vaccines with plasticity

Backed by exceptional science

Team

Founded in 2019 by a technical team of vaccine and software developers, Baseimmune is accelerating discovery of novel and cross-protective vaccines. Our founders pioneered the use of computational approaches to design cross-protective vaccines against various infectious diseases while at the Jenner Institute University of Oxford with two candidates in clinical trials.

Leadership

Co-founder, CEO

Co-founder, CSO

Co-founder, CTO

Board of Directors

Jamie

Macfarlane

Creator Fund

Hussein

Kanji

Hoxton Ventures

Alex 

Wilson

IQ Capital

Joshua

Blight

Baseimmune

Ariane

Gomes

Baseimmune

Phillip

Kemlo

Baseimmune

Advisory Board

Danny

Goovaerts

Prof. Jake

Baum

Prof. Molly Stevens

Veterinary Commercial Advisor

Scientific Advisor

Scientific Advisor

Pipeline

Our early-stage pipeline includes two human vaccines against Malaria (BSI002) and a pancoronavirus vaccine (BSI001), and a veterinary vaccine against African Swine Fever (BSI001). All candidates are currently being tested as mRNA/LNP or viral vectors.

Human

Pan-Coronavirus Vaccine

DISCOVERY

PRECLINICAL

BSI002

Universal Malaria Vaccine

BSI003

Veterinary

FEASIBILITY

EARLY-STAGE DEVELOPMENT

Universal African Swine Fever Vaccine

BSI001

News & Careers

Career Opportunities

Join the team to harness the power of our computational platform to design and create variant-proof vaccines. Check our careers page for available positions.

Working with world-class

Funded and supported by

Contact

If you’d like to know more, contact us.

© 2023 Baseimmune. All rights reserved

London BioScience Innovation Centre, 2 Royal College Street, London, NW1 0NH

Designed and created with love by the Baseimmune Team ♥︎


baseimmune

®

This website makes use of cookies. Please see our privacy policy for details.

Deny

OK